Alto Neuroscience (NYSE:ANRO) Stock: Insider Jr. Michael Conick Hanley Sells 2,104 Shares

Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) COO Michael Hanley sold 2,104 shares of the company’s stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $26.82, for a total value of $56,429.28. Following the completion of the sale, the chief operating officer owned 17,729 shares in the company, valued at $475,491.78. The trade was a 10.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Jr. Michael Conick Hanley also recently made the following trade(s):

  • On Wednesday, November 18th, Michael Hanley sold 2,896 shares of Alto Neuroscience stock. The shares were sold at an average price of $26.48, for a total value of $76,686.08.
  • On Monday, November 16th, Michael Hanley sold 70,000 shares of Alto Neuroscience stock. The stock was sold at an average price of $27.68, for a total transaction of $1,937,600.00.

Alto Neuroscience Trading Up 2.1%

ANRO opened at $26.45 on Friday. Alto Neuroscience, Inc. has a fifty-two week low of $12.51 and a fifty-two week high of $37.48. The company has a quick ratio of 18.12, a current ratio of 18.12 and a debt-to-equity ratio of 0.04. The company has a fifty day moving average of $25.72 and a two-hundred day moving average of $24.85.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.13. As a group, analysts forecast that Alto Neuroscience, Inc. will post -2.48 EPS for the current fiscal year.

Key Stories Impacting Alto Neuroscience

Here are a few of the latest stories about ANRO:

  • Positive Sentiment: Alto reported a quarterly loss of $0.54 per share, narrower than the $0.67 loss analysts expected. That earnings beat may support the shares, although the reported loss was wider than in the year-earlier quarter. Alto Neuroscience quarterly results and valuation analysis
  • Neutral Sentiment: A recent article questioned whether ANRO’s premium valuation is justified, raising a potential risk if investors see limited support for its valuation. Alto Neuroscience valuation analysis
  • Negative Sentiment: COO Michael Hanley sold a total of about 75,000 shares in transactions on Nov. 16–18, worth roughly $2.07 million, substantially reducing his reported holdings. The sales could unsettle investors, though insider transactions do not by themselves indicate the company’s prospects. SEC Form 4 filing

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Sterling Capital Management LLC grew its stake in shares of Alto Neuroscience by 1,045.7% in the third quarter. Sterling Capital Management LLC now owns 1,054 shares of the company’s stock valued at $27,000 after buying an additional 962 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in Alto Neuroscience by 48,581.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 5,355 shares of the company’s stock worth $137,000 after buying an additional 5,344 shares in the last quarter. GK Wealth Management LLC purchased a new position in Alto Neuroscience in the 2nd quarter valued at approximately $226,000. Empowered Funds LLC purchased a new stake in shares of Alto Neuroscience during the third quarter worth $299,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Alto Neuroscience in the first quarter valued at $534,000.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ANRO. Zacks Research raised shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 20th. HC Wainwright reiterated a “buy” rating on shares of Alto Neuroscience in a research report on Thursday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Tuesday, October 27th. Wall Street Zen lowered shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Finally, BTIG Research reiterated a “buy” rating and issued a $37.00 target price on shares of Alto Neuroscience in a report on Wednesday, November 11th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.88.

Read Our Latest Stock Report on Alto Neuroscience

Alto Neuroscience Company Profile

(Get Free Report)

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.

Featured Stories

Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.